The results highlight the importance of age, LDH, β2-microglobulin, CRP, LYM, and B symptoms as critical prognostic markers for guiding treatment decisions and improving patient outcomes in DLBCL. This evidence concerns the gene CRP and diffuse large B-cell lymphoma.